Accès à distance ? S'identifier sur le proxy UCLouvain
Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.
Onglets principaux
Type de document | Article de périodique (Journal article) – Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't |
---|---|
Type d'accès | Accès restreint |
Année de publication | 2007 |
Information sur le périodique | "Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA" - Vol. 18, no. 9, p. 1211-8 (2007) |
Peer reviewed | oui |
issn | 0937-941X |
Statut de la publication | Publié |
Affiliations |
UCL
- (SLuc) Service de rhumatologie UCL - MD/MINT - Département de médecine interne |
MESH Subject | Adult ; Bone Density Conservation Agents - administration & dosage - adverse effects ; Diphosphonates - administration & dosage - adverse effects ; Double-Blind Method ; Female ; Fractures, Bone - prevention & control ; Humans ; Imidazoles - administration & dosage - adverse effects ; Middle Aged ; Osteoporosis, Postmenopausal - drug therapy ; Treatment Outcome |
Liens |
- Mellström DD, Sörensen OH, Goemaere S et al (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462–468
- Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 350:1189–1199
- Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661
- Garnero P, Sornay-Rendu E, Claustrat B et al (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:1526–1536
- Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282(14):1344–1352, Oct 13
- Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. Fracture Intervention Trial Study Group. J Bone Miner Res 19:1250–1258
- Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
- Recker R, Stakkestad JA, Chesnut CH et al (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890–899
- Reginster JY, Christiansen C, Roux C et al (2001) Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporosis Int 12:169–177
Référence bibliographique | Devogelaer, Jean-Pierre ; Brown, J P ; Burckhardt, P. ; Meunier, P J ; Goemaere, S. ; et. al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.. In: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, Vol. 18, no. 9, p. 1211-8 (2007) |
---|---|
Permalien | http://hdl.handle.net/2078.1/10974 |